HDAC1 and peripheral T-cell lymphoma, not otherwise specified: Early targeting of this family of 11 enzymes(HDAC1–11) afforded a first generation of broadly acting inhibitorswith medicinal applications in oncology, specifically in cutaneousand peripheral T-cell lymphomas and in multiple myeloma.